Fed Governor Cook sues Trump over firing attempt
Haleon plc (LSE/NYSE:HLN), a global consumer health leader with a market capitalization of $44 billion, disclosed today that two of its executives have acquired shares as part of the company’s Share Reward Plan. The transactions were carried out on the London Stock Exchange (LON:LSEG) on Monday, with the stock trading near its 52-week high. According to InvestingPro analysis, the company currently appears fairly valued based on its Fair Value assessment.
Adrian Morris, General Counsel, and Tamara Rogers (NYSE:ROG), Chief Marketing Officer, both Persons Discharging Managerial Responsibilities (PDMRs) at Haleon, participated in the acquisition of Partnership Shares and were subsequently awarded Matching Shares under the plan.
Each executive purchased 32 ordinary shares at a price of £3.9249 per share and received an additional 32 matching shares at no cost. The company maintains a healthy financial profile, with InvestingPro data showing a robust gross profit margin of 62.2%.
The total number of shares involved in these transactions for each PDMR was 64. The Share Reward Plan is designed to align the interests of the company’s management with those of its shareholders.
Haleon, known for brands such as Advil, Sensodyne, and Centrum, operates in various health-related categories including Oral Health, Pain Relief, Respiratory Health, and Vitamins, Minerals, and Supplements.
With the company’s next earnings report scheduled for February 27, investors can access comprehensive analysis and additional insights through the detailed Pro Research Report available on InvestingPro, which covers this and 1,400+ other top stocks.
The company’s commitment to delivering better everyday health is underpinned by trusted science and innovation. This news comes as part of a routine disclosure in compliance with UK Market Abuse Regulation, indicating transparency in the dealings of Haleon’s management team.
The information provided is based on a press release statement from the company.
In other recent news, Haleon, a well-known consumer health company, reported an updated total number of shares and voting rights in a recent regulatory filing. The company also disclosed that two of its key executives acquired shares as part of the company’s Share Reward Plan.
Meanwhile, Morgan Stanley (NYSE:MS) revised its price target for Haleon to $10.05 from the previous $10.20 while maintaining an Equalweight rating on the stock. Jefferies reaffirmed its Buy rating on Haleon, maintaining a price target of GBP4.50. However, Bernstein analysts downgraded Haleon stock from ’Outperform’ to ’Market Perform’ while raising their price target from GBP3.80 to GBP4.00.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.